Mifepristone Treatment Promotes Testicular Leydig Cell Tumor Progression in Transgenic Mice

SIMPLE SUMMARY: Recently, the antiprogestin activity of selective progesterone receptor (PR) modulator mifepristone (MF) has proven unsuccessful as a potential anti-cancer agent in various clinical trials. Herein, we analyzed the effects of MF treatment on Leydig cell tumor (LCT) progression in a tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponikwicka-Tyszko, Donata, Chrusciel, Marcin, Pulawska, Kamila, Bernaczyk, Piotr, Sztachelska, Maria, Guo, Peilan, Li, Xiangdong, Toppari, Jorma, Huhtaniemi, Ilpo T., Wołczyński, Slawomir, Rahman, Nafis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694279/
https://www.ncbi.nlm.nih.gov/pubmed/33158280
http://dx.doi.org/10.3390/cancers12113263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694279/
https://www.ncbi.nlm.nih.gov/pubmed/33158280
http://dx.doi.org/10.3390/cancers12113263

Ejemplares similares